1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Clinical Psychology
  4. Volume 17, 2021
  5. Article

Annual Review of Clinical Psychology

Volume 17, 2021

Clinical Neuroscience of Addiction: What Clinical Psychologists Need to Know and Why

Abstract

The last three decades in psychological research have been marked by interdisciplinary science. Addiction represents a prime example of a disorder marked by a complex interaction among psychosocial and biological factors. This review highlights critical findings in the basic neuroscience of addiction and translates them into clinical language that can inform clinical psychologists in their research, teaching, and practice. From mechanisms of reward processing, learning and memory, allostasis, incentive-sensitization, withdrawal, tolerance, goal-directed decision making, habit learning, genetics, inflammation, and the microbiome, the common theme of this review is to illustrate the clinical utility of basic neuroscience research and to identify opportunities for clinical science. The thoughtful integration of basic and clinical science provides a powerful tool to fulfill the scientific mission of improving health care. Clinical psychologists have a crucial role to play in the translational science of addiction.

Keyword(s): addiction, allostasis, clinical neuroscience, incentive-sensitization, neuroadaptation, translational science
Loading

Article metrics loading...

/content/journals/10.1146/annurev-clinpsy-081219-114309
2021-05-07
2025-04-27
Loading full text...

Full text loading...

/deliver/fulltext/clinpsy/17/1/annurev-clinpsy-081219-114309.html?itemId=/content/journals/10.1146/annurev-clinpsy-081219-114309&mimeType=html&fmt=ahah

Literature Cited

  1. Ahmed SH, Koob GF. 2005. Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. Psychopharmacology 180:3473–90 https://doi.org/10.1007/s00213-005-2180-z
    [Crossref] [Google Scholar]
  2. Amlung M, Marsden E, Holshausen K, Morris V, Patel H et al. 2019. Delay discounting as a transdiagnostic process in psychiatric disorders: a meta-analysis. JAMA Psychiatry 76:111176–86
     [Google Scholar]
  3. Amstadter AB, Maes HH, Sheerin CM, Myers JM, Kendler KS. 2016. The relationship between genetic and environmental influences on resilience and on common internalizing and externalizing psychiatric disorders. Soc. Psychiatry Psychiatr. Epidemiol. 51:5669–78 https://doi.org/10.1007/s00127-015-1163-6
    [Crossref] [Google Scholar]
  4. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R et al. 2008. An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65:2135–44 https://doi.org/10.1001/archpsyc.65.2.135
    [Crossref] [Google Scholar]
  5. Archer M, Harwood H, Stevelink S, Rafferty L, Greenberg N. 2020. Community reinforcement and family training and rates of treatment entry: a systematic review. Addiction 115:61024–37 https://doi.org/10.1111/add.14901
    [Crossref] [Google Scholar]
  6. Augier E, Barbier E, Dulman RS, Licheri V, Augier G et al. 2018. A molecular mechanism for choosing alcohol over an alternative reward. Science 360:63951321–26 https://doi.org/10.1126/science.aao1157
    [Crossref] [Google Scholar]
  7. Balleine BW, O'Doherty JP. 2010. Human and rodent homologies in action control: corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 35:148–69 https://doi.org/10.1038/npp.2009.131
    [Crossref] [Google Scholar]
  8. Bedi G, Martinez D, Levin FR, Comer S, Haney M. 2017. Addiction as a brain disease does not promote injustice. Nat. Hum. Behav. 1:9610 https://doi.org/10.1038/s41562-017-0203-5
    [Crossref] [Google Scholar]
  9. Belkaid Y, Hand TW. 2014. Role of the microbiota in immunity and inflammation. Cell 157:1121–41 https://doi.org/10.1016/j.cell.2014.03.011
    [Crossref] [Google Scholar]
  10. Berridge KC, Robinson TE. 2003. Parsing reward. Trends Neurosci 26:9507–13 https://doi.org/10.1016/S0166-2236(03)00233-9
    [Crossref] [Google Scholar]
  11. Berridge KC, Robinson TE, Aldridge JW. 2009. Dissecting components of reward: ‘liking’, ‘wanting’, and learning. Curr. Opin. Pharmacol. 9:165–73 https://doi.org/10.1016/j.coph.2008.12.014
    [Crossref] [Google Scholar]
  12. Bickel WK, Johnson MW, Koffarnus MN, MacKillop J, Murphy JG. 2014. The behavioral economics of substance use disorders: reinforcement pathologies and their repair. Annu. Rev. Clin. Psychol. 10:641–77 https://doi.org/10.1146/annurev-clinpsy-032813-153724
    [Crossref] [Google Scholar]
  13. Bierut LJ. 2011. Genetic vulnerability and susceptibility to substance dependence. Neuron 69:4618–27 https://doi.org/10.1016/j.neuron.2011.02.015
    [Crossref] [Google Scholar]
  14. Blednov YA, Benavidez JM, Geil C, Perra S, Morikawa H, Harris RA. 2011. Activation of inflammatory signaling by lipopolysaccharide produces a prolonged increase of voluntary alcohol intake in mice. Brain Behav. Immun. 25:Suppl. 1S92–105 https://doi.org/10.1016/j.bbi.2011.01.008
    [Crossref] [Google Scholar]
  15. Blednov YA, Ponomarev I, Geil C, Bergeson S, Koob GF, Harris RA. 2012. Neuroimmune regulation of alcohol consumption: behavioral validation of genes obtained from genomic studies. Addict. Biol. 17:1108–20 https://doi.org/10.1111/j.1369-1600.2010.00284.x
    [Crossref] [Google Scholar]
  16. Bornstein AM, Pickard H. 2020.. “ Chasing the first high”: memory sampling in drug choice. Neuropsychopharmacology 45:6907–15
     [Google Scholar]
  17. Bujarski S, Hutchison KE, Prause N, Ray LA. 2017. Functional significance of subjective response to alcohol across levels of alcohol exposure. Addict. Biol. 22:1235–45 https://doi.org/10.1111/adb.12293
    [Crossref] [Google Scholar]
  18. Bujarski S, Jentsch JD, Roche DJO, Ramchandani VA, Miotto K, Ray LA. 2018. Differences in the subjective and motivational properties of alcohol across alcohol use severity: application of a novel translational human laboratory paradigm. Neuropsychopharmacology 43:91891–99 https://doi.org/10.1038/s41386-018-0086-9
    [Crossref] [Google Scholar]
  19. Bujarski S, Ray LA. 2014. Subjective response to alcohol and associated craving in heavy drinkers versus alcohol dependents: an examination of Koob's allostatic model in humans. Drug Alcohol Depend 140:161–67 https://doi.org/10.1016/j.drugalcdep.2014.04.015
    [Crossref] [Google Scholar]
  20. Button TM, Rhee SH, Hewitt JK, Young SE, Corley RP, Stallings MC. 2007. The role of conduct disorder in explaining the comorbidity between alcohol and illicit drug dependence in adolescence. Drug Alcohol Depend 87:146–53 https://doi.org/10.1016/j.drugalcdep.2006.07.012
    [Crossref] [Google Scholar]
  21. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. 1999. Limbic activation during cue-induced cocaine craving. Am. J. Psychiatry 156:111–18
     [Google Scholar]
  22. Cichon S, Craddock N, Daly M, Faraone SV, Gejman PV et al. 2009. Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am. J. Psychiatry 166:5540–56 https://doi.org/10.1176/appi.ajp.2008.08091354
    [Crossref] [Google Scholar]
  23. Conklin CA, Tiffany ST 2002. Applying extinction research and theory to cue-exposure addiction treatments. Addiction 97:2155–67
     [Google Scholar]
  24. Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK et al. 2016. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict. Biol. 21:4895–903
     [Google Scholar]
  25. Courtney KE, Schacht JP, Hutchison K, Roche DJ, Ray LA. 2016. Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addict. Biol. 21:13–22 https://doi.org/10.1111/adb.12314
    [Crossref] [Google Scholar]
  26. Cservenka A, Courtney KE, Ghahremani DG, Hutchison KE, Ray LA. 2017. Development, initial testing and challenges of an ecologically valid reward prediction error fMRI task for alcoholism. Alcohol Alcohol 52:5617–24 https://doi.org/10.1093/alcalc/agx037
    [Crossref] [Google Scholar]
  27. de Timary P, Stärkel P, Delzenne NM, Leclercq S. 2017. A role for the peripheral immune system in the development of alcohol use disorders?. Neuropharmacology 122:148–60 https://doi.org/10.1016/j.neuropharm.2017.04.013
    [Crossref] [Google Scholar]
  28. Dimoff JD, Sayette MA, Norcross JC. 2017. Addiction training in clinical psychology: Are we keeping up with the rising epidemic?. Am. Psychol. 72:7689–95
     [Google Scholar]
  29. Dolan RJ, Dayan P. 2013. Goals and habits in the brain. Neuron 80:2312–25 https://doi.org/10.1016/j.neuron.2013.09.007
    [Crossref] [Google Scholar]
  30. Ducci F, Goldman D. 2008. Genetic approaches to addiction: genes and alcohol. Addiction 103:91414–28 https://doi.org/10.1111/j.1360-0443.2008.02203.x
    [Crossref] [Google Scholar]
  31. Duncan LE, Keller MC. 2011. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am. J. Psychiatry 168:101041–49
     [Google Scholar]
  32. Duncan LE, Ostacher M, Ballon J. 2019. How genome-wide association studies (GWAS) made traditional candidate gene studies obsolete. Neuropsychopharmacology 44:91518–23 https://doi.org/10.1038/s41386-019-0389-5
    [Crossref] [Google Scholar]
  33. Edenberg HJ, Gelernter J, Agrawal A. 2019. Genetics of alcoholism. Curr. Psychiatry Rep. 21:426 https://doi.org/10.1007/s11920-019-1008-1
    [Crossref] [Google Scholar]
  34. Egli M. 2018. Advancing pharmacotherapy development from preclinical animal studies. Handbook of Experimental Pharmacology, Vol. 248: The Neuropharmacology of Alcohol KA Grant, DM Lovinger 537–78 Cham, Switz: Springer https://doi.org/10.1007/164_2017_85
    [Crossref] [Google Scholar]
  35. Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. 2015. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. Curr. Rev. 37:2223–36
     [Google Scholar]
  36. Epstein DH. 2020. Let's agree to agree: a comment on Hogarth (2020), with a plea for not-so-competing theories of addiction. Neuropsychopharmacology 45:5715–16
     [Google Scholar]
  37. Erickson EK, Grantham EK, Warden AS, Harris RA. 2019. Neuroimmune signaling in alcohol use disorder. Pharmacol. Biochem. Behav. 177:34–60 https://doi.org/10.1016/j.pbb.2018.12.007
    [Crossref] [Google Scholar]
  38. Everitt BJ, Robbins TW. 2005. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8:111481–89 https://doi.org/10.1038/nn1579
    [Crossref] [Google Scholar]
  39. Everitt BJ, Robbins TW. 2016. Drug addiction: updating actions to habits to compulsions ten years on. Annu. Rev. Psychol. 67:23–50 https://doi.org/10.1146/annurev-psych-122414-033457
    [Crossref] [Google Scholar]
  40. Filbey FM, Claus E, Audette AR, Niculescu M, Banich MT et al. 2008. Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry. Neuropsychopharmacology 33:61391–401 https://doi.org/10.1038/sj.npp.1301513
    [Crossref] [Google Scholar]
  41. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE. 2009. Marijuana craving in the brain. PNAS 106:3113016–21 https://doi.org/10.1073/pnas.0903863106
    [Crossref] [Google Scholar]
  42. Freeman K, Brureau A, Vadigepalli R, Staehle MM, Brureau MM et al. 2012. Temporal changes in innate immune signals in a rat model of alcohol withdrawal in emotional and cardiorespiratory homeostatic nuclei. J. Neuroinflammation 9:197 https://doi.org/10.1186/1742-2094-9-97
    [Crossref] [Google Scholar]
  43. Gelernter J, Kranzler HR. 2009. Genetics of alcohol dependence. Hum. Genet. 126:191–99 https://doi.org/10.1007/s00439-009-0701-2
    [Crossref] [Google Scholar]
  44. Gershon ES, Alliey-Rodriguez N, Liu C. 2011. After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am. J. Psychiatry 168:3253–56 https://doi.org/10.1176/appi.ajp.2010.10091340
    [Crossref] [Google Scholar]
  45. Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. 2018. Current understanding of the human microbiome. Nat. Med. 24:4392–400 https://doi.org/10.1038/nm.4517
    [Crossref] [Google Scholar]
  46. Golan D, Lander ES, Rosset S 2014. Measuring missing heritability: inferring the contribution of common variants. PNAS 111:49E5272–81 https://doi.org/10.1073/pnas.1419064111
    [Crossref] [Google Scholar]
  47. Gordon JA. 2019. From neurobiology to novel medications: a principled approach to translation. Am. J. Psychiatry 176:6425–27
     [Google Scholar]
  48. Gottesman I, Gould TD. 2003. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160:4636–45
     [Google Scholar]
  49. Graybiel AM. 2008. Habits, rituals, and the evaluative brain. Annu. Rev. Neurosci. 31:359–87 https://doi.org/10.1146/annurev.neuro.29.051605.112851
    [Crossref] [Google Scholar]
  50. Grifell M, Hart C. 2018. Is drug addiction a brain disease?. Am. Sci. 106:3160–67
     [Google Scholar]
  51. Grodin EN, Bujarski S, Venegas A, Baskerville WA, Nieto SJ et al. 2019. Reward, relief and habit drinking: initial validation of a brief assessment tool. Alcohol Alcohol 54:6574–83 https://doi.org/10.1093/alcalc/agz075
    [Crossref] [Google Scholar]
  52. Grodin EN, Montoya AK, Bujarski S, Ray LA. 2020. Modeling motivation for alcohol in humans using traditional and machine learning approaches. Addict. Biol. In press. https://doi.org/10.1111/adb.12949
    [Crossref] [Google Scholar]
  53. Grodin EN, Ray LA. 2019. The use of functional magnetic resonance imaging to test pharmacotherapies for alcohol use disorder: a systematic review. Alcohol. Clin. Exp. Res. 43:102038–56 https://doi.org/10.1111/acer.14167
    [Crossref] [Google Scholar]
  54. Grodin EN, Sussman L, Sundby K, Brennan GM, Diazgranados N et al. 2018. Neural correlates of compulsive alcohol seeking in heavy drinkers. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 3:121022–31 https://doi.org/10.1016/j.bpsc.2018.06.009
    [Crossref] [Google Scholar]
  55. Han JH, Kushner SA, Yiu AP, Hsiang HLL, Buch T et al. 2009. Selective erasure of a fear memory. Science 323:59201492–96
     [Google Scholar]
  56. Hartwell EE, Kranzler HR. 2019. Pharmacogenetics of alcohol use disorder treatments: an update. Expert Opin. Drug Metab. Toxicol. 15:7553–64 https://doi.org/10.1080/17425255.2019.1628218
    [Crossref] [Google Scholar]
  57. He J, Crews FT. 2008. Increased MCP-1 and microglia in various regions of the human alcoholic brain. Exp. Neurol. 210:2349–58
     [Google Scholar]
  58. Heberlein A, Käser M, Lichtinghagen R, Rhein M, Lenz B et al. 2014. TNF-α and IL-6 serum levels: neurobiological markers of alcohol consumption in alcohol-dependent patients?. Alcohol 48:7671–76 https://doi.org/10.1016/j.alcohol.2014.08.003
    [Crossref] [Google Scholar]
  59. Heijtz RD, Wang S, Anuar F, Qian Y, Björkholm B et al. 2011. Normal gut microbiota modulates brain development and behavior. PNAS 108:73047–52
     [Google Scholar]
  60. Heilig M, Egli M, Crabbe JC, Becker HC. 2010. Acute withdrawal, protracted abstinence and negative affect in alcoholism: Are they linked?. Addict. Biol. 15:2169–84 https://doi.org/10.1111/j.1369-1600.2009.00194.x
    [Crossref] [Google Scholar]
  61. Heilig M, Leggio L. 2016. What the alcohol doctor ordered from the neuroscientist: theragnostic biomarkers for personalized treatments. Progress in Brain Research, Vol. 224: Neuroscience for Addiction Medicine: From Prevention to Rehabilitation—Methods and Interventions H Ekhtiari, MP Paulus 401–18 Amsterdam: Elsevier https://doi.org/10.1016/bs.pbr.2015.07.023
    [Crossref] [Google Scholar]
  62. Heilig M, Sommer WH, Spanagel R. 2016. The need for treatment responsive translational biomarkers in alcoholism research. Curr. Top. Behav. Neurosci. 28:151–71 https://doi.org/10.1007/7854_2015_5006
    [Crossref] [Google Scholar]
  63. Hofmann SG, Fang A, Gutner CA. 2014. Cognitive enhancers for the treatment of anxiety disorders. Restor. Neurol. Neurosci. 32:1183–95 https://doi.org/10.3233/rnn-139002
    [Crossref] [Google Scholar]
  64. Hogarth L. 2020. Addiction is driven by excessive goal-directed drug choice under negative affect: translational critique of habit and compulsion theory. Neuropsychopharmacology 45:5720–35 https://doi.org/10.1038/s41386-020-0600-8
    [Crossref] [Google Scholar]
  65. Insel TR, Cuthbert B, Garvey M, Heinssen R, Pine DS et al. 2010. Research Domain Criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167:7748–51 https://doi.org/10.1176/appi.ajp.2010.09091379
    [Crossref] [Google Scholar]
  66. Insel TR, Quirion R. 2005. Psychiatry as a clinical neuroscience discipline. JAMA 294:172221–24 https://doi.org/10.1001/jama.294.17.2221
    [Crossref] [Google Scholar]
  67. Jadhav KS, Peterson VL, Halfon O, Ahern G, Fouhy F et al. 2018. Gut microbiome correlates with altered striatal dopamine receptor expression in a model of compulsive alcohol seeking. Neuropharmacology 141:249–59 https://doi.org/10.1016/j.neuropharm.2018.08.026
    [Crossref] [Google Scholar]
  68. Jones JD, Comer SD, Kranzler HR. 2015. The pharmacogenetics of alcohol use disorder. Alcohol. Clin. Exp. Res. 39:3391–402 https://doi.org/10.1111/acer.12643
    [Crossref] [Google Scholar]
  69. Kalant H. 2010. What neurobiology cannot tell us about addiction. Addiction 105:5780–89 https://doi.org/10.1111/j.1360-0443.2009.02739.x
    [Crossref] [Google Scholar]
  70. Kalivas PW, Volkow ND. 2005. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 162:81403–13 https://doi.org/10.1176/appi.ajp.162.8.1403
    [Crossref] [Google Scholar]
  71. Kendler KS, Karkowski LM, Neale MC, Prescott CA. 2000. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch. Gen. Psychiatry 57:3261–69
     [Google Scholar]
  72. Kendler KS, Prescott CA, Myers J, Neale MC 2003. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch. Gen. Psychiatry 60:9929–37 https://doi.org/10.1001/archpsyc.60.9.929
    [Crossref] [Google Scholar]
  73. Kiluk BD, Fitzmaurice GM, Strain EC, Weiss RD. 2019. What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?. Addiction 114:19–15 https://doi.org/10.1111/add.14289
    [Crossref] [Google Scholar]
  74. King AC, Hasin D, O'Connor SJ, McNamara PJ, Cao D 2016. A prospective 5-year re-examination of alcohol response in heavy drinkers progressing in alcohol use disorder. Biol. Psychiatry 79:6489–98 https://doi.org/10.1016/j.biopsych.2015.05.007
    [Crossref] [Google Scholar]
  75. Kiraly DD, Walker DM, Calipari ES, Labonte B, Issler O et al. 2016. Alterations of the host microbiome affect behavioral responses to cocaine. Sci. Rep. 6:35455 https://doi.org/10.1038/srep35455
    [Crossref] [Google Scholar]
  76. Koob GF. 1992. Neural mechanisms of drug reinforcement. Ann. N.Y. Acad. Sci. 654:171–91
     [Google Scholar]
  77. Koob GF. 2003. Alcoholism: allostasis and beyond. Alcohol. Clin. Exp. Res. 27:2232–43 https://doi.org/10.1097/01.ALC.0000057122.36127.C2
    [Crossref] [Google Scholar]
  78. Koob GF, Kreek MJ. 2007. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am. J. Psychiatry 164:81149–59 https://doi.org/10.1176/appi.ajp.2007.05030503
    [Crossref] [Google Scholar]
  79. Koob GF, Le Moal M 1997. Drug abuse: hedonic homeostatic dysregulation. Science 278:533552–58
     [Google Scholar]
  80. Koob GF, Schulkin J. 2019. Addiction and stress: an allostatic view. Neurosci. Biobehav. Rev. 106:245–62 https://doi.org/10.1016/j.neubiorev.2018.09.008
    [Crossref] [Google Scholar]
  81. Koob GF, Volkow ND. 2010. Neurocircuitry of addiction. Neuropsychopharmacology 35:1217–38 https://doi.org/10.1038/npp.2009.110
    [Crossref] [Google Scholar]
  82. Kos MZ, Yan J, Dick DM, Agrawal A, Bucholz KK et al. 2013. Common biological networks underlie genetic risk for alcoholism in African- and European-American populations. Genes Brain Behav 12:5532–42 https://doi.org/10.1111/gbb.12043
    [Crossref] [Google Scholar]
  83. Kranzler HR, Zhou H, Kember RL, Vickers Smith R, Justice AC et al. 2019. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat. Commun. 10:11499 https://doi.org/10.1038/s41467-019-09480-8
    [Crossref] [Google Scholar]
  84. Kwako LE, Bickel WK, Goldman D. 2018. Addiction biomarkers: dimensional approaches to understanding addiction. Trends Mol. Med. 24:2121–28 https://doi.org/10.1016/j.molmed.2017.12.007
    [Crossref] [Google Scholar]
  85. Kwako LE, Momenan R, Grodin EN, Litten RZ, Koob GF, Goldman D. 2017. Addictions Neuroclinical Assessment: a reverse translational approach. Neuropharmacology 122:254–64 https://doi.org/10.1016/j.neuropharm.2017.03.006
    [Crossref] [Google Scholar]
  86. Kwako LE, Schwandt ML, Ramchandani VA, Diazgranados N, Koob GF et al. 2019. Neurofunctional domains derived from deep behavioral phenotyping in alcohol use disorder. Am. J. Psychiatry 176:9744–53 https://doi.org/10.1176/appi.ajp.2018.18030357
    [Crossref] [Google Scholar]
  87. Leclercq S, De Saeger C, Delzenne N, de Timary P, Stärkel P. 2014a. Role of inflammatory pathways, blood mononuclear cells, and gut-derived bacterial products in alcohol dependence. Biol. Psychiatry 76:9725–33 https://doi.org/10.1016/j.biopsych.2014.02.003
    [Crossref] [Google Scholar]
  88. Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F et al. 2014b. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. PNAS 111:42E4485–93
     [Google Scholar]
  89. Lee K, Vuong HE, Nusbaum DJ, Hsiao EY, Evans CJ, Taylor AM. 2018. The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence. Neuropsychopharmacology 43:132606–14
     [Google Scholar]
  90. Leggio L, Kenna GA, Fenton M, Bonenfant E, Swift RM. 2009. Typologies of alcohol dependence. From Jellinek to genetics and beyond. Neuropsychol. Rev. 19:1115–29 https://doi.org/10.1007/s11065-008-9080-z
    [Crossref] [Google Scholar]
  91. Liu J, Lewohl JM, Harris RA, Iyer VR, Dodd PR et al. 2006. Patterns of gene expression in the frontal cortex discriminate alcoholic from nonalcoholic individuals. Neuropsychopharmacology 31:71574–82
     [Google Scholar]
  92. Luczynski P, McVey Neufeld KA, Oriach CS, Clarke G, Dinan TG, Cryan JF 2016. Growing up in a bubble: using germ-free animals to assess the influence of the gut microbiota on brain and behavior. Int. J. Neuropsychopharmacol. 19:8pyw020 https://doi.org/10.1093/ijnp/pyw020
    [Crossref] [Google Scholar]
  93. Luijten M, Gillan CM, de Wit S, Franken IHA, Robbins TW, Ersche KD. 2020. Goal-directed and habitual control in smokers. Nicotine Tob. Res. 22:2188–95 https://doi.org/10.1093/ntr/ntz001
    [Crossref] [Google Scholar]
  94. MacKillop J, Amlung MT, Few LR, Ray LA, Sweet LH, Munafo MR. 2011. Delayed reward discounting and addictive behavior: a meta-analysis. Psychopharmacology 216:3305–21 https://doi.org/10.1007/s00213-011-2229-0
    [Crossref] [Google Scholar]
  95. Malvaez M, Wassum KM. 2018. Regulation of habit formation in the dorsal striatum. Curr. Opin. Behav. Sci. 20:67–74 https://doi.org/10.1016/j.cobeha.2017.11.005
    [Crossref] [Google Scholar]
  96. Mann K, Aubin HJ, Witkiewitz K. 2017. Reduced drinking in alcohol dependence treatment, what is the evidence?. Eur. Addict. Res. 23:5219–30
     [Google Scholar]
  97. Mann K, Roos CR, Hoffmann S, Nakovics H, Lemenager T et al. 2018. Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes. Neuropsychopharmacology 43:4891–99 https://doi.org/10.1038/npp.2017.282
    [Crossref] [Google Scholar]
  98. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA et al. 2009. Finding the missing heritability of complex diseases. Nature 461:7265747–53 https://doi.org/10.1038/nature08494
    [Crossref] [Google Scholar]
  99. Mayfield J, Harris RA. 2017. The neuroimmune basis of excessive alcohol consumption. Neuropsychopharmacology 42:1376 https://doi.org/10.1038/npp.2016.177
    [Crossref] [Google Scholar]
  100. McBride WJ, Kimpel MW, McClintick JN, Ding ZM, Hauser SR et al. 2013. Changes in gene expression within the ventral tegmental area following repeated excessive binge-like alcohol drinking by alcohol-preferring (P) rats. Alcohol 47:5367–80
     [Google Scholar]
  101. McLellan AT. 2002. Have we evaluated addiction treatment correctly? Implications from a chronic care perspective. Addiction 97:3249–52
     [Google Scholar]
  102. Meckel KR, Kiraly DD. 2019. A potential role for the gut microbiome in substance use disorders. Psychopharmacology 236:51513–30 https://doi.org/10.1007/s00213-019-05232-0
    [Crossref] [Google Scholar]
  103. Meehl PE. 1972. Specific genetic etiology, psychodynamics, and therapeutic nihilism. Int. J. Ment. Health 1:1–210–27
     [Google Scholar]
  104. Monti PM, Tidey J, Czachowski CL, Grant KA, Rohsenow DJ et al. 2004. Building bridges: the transdisciplinary study of craving from the animal laboratory to the lamppost. Alcohol. Clin. Exp. Res. 28:2279–87
     [Google Scholar]
  105. Morris LS, Dowell NG, Cercignani M, Harrison NA, Voon V. 2018. Binge drinking differentially affects cortical and subcortical microstructure. Addict. Biol. 23:1403–11
     [Google Scholar]
  106. Nieto SJ, Grodin EN, Ray LA. 2020. On the path toward personalized medicine: implications of pharmacogenetic studies of alcohol use disorder medications. Expert Rev. Precis. Med. Drug Dev. 5:143–54
     [Google Scholar]
  107. Nolen-Hoeksema S, Watkins ER. 2011. A heuristic for developing transdiagnostic models of psychopathology: explaining multifinality and divergent trajectories. Perspect. Psychol. Sci. 6:6589–609
     [Google Scholar]
  108. Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP et al. 2015. Naltrexone versus placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA Psychiatry 72:5430–37 https://doi.org/10.1001/jamapsychiatry.2014.3053
    [Crossref] [Google Scholar]
  109. Ostergren JE, Hammer RR, Dingel MJ, Koenig BA, McCormick JB. 2014. Challenges in translational research: the views of addiction scientists. PLOS ONE 9:4e93482 https://doi.org/10.1371/journal.pone.0093482
    [Crossref] [Google Scholar]
  110. Pascual M, Baliño P, Aragón CM, Guerri C. 2015. Cytokines and chemokines as biomarkers of ethanol-induced neuroinflammation and anxiety-related behavior: role of TLR4 and TLR2. Neuropharmacology 89:352–59
     [Google Scholar]
  111. Peterson VL, Jury NJ, Cabrera-Rubio R, Draper LA, Crispie F et al. 2017. Drunk bugs: Chronic vapour alcohol exposure induces marked changes in the gut microbiome in mice. Behav. Brain Res. 323:172–76
     [Google Scholar]
  112. Prescott CA, Kendler KS. 1999. Genetic and environmental contributions to alcohol abuse and dependence in a population-based sample of male twins. Am. J. Psychiatry 156:134–40
     [Google Scholar]
  113. Qin L, He J, Hanes RN, Pluzarev O, Hong JS, Crews FT. 2008. Increased systemic and brain cytokine production and neuroinflammation by endotoxin following ethanol treatment. J. Neuroinflammation 5:110 https://doi.org/10.1186/1742-2094-5-10
    [Crossref] [Google Scholar]
  114. Ray LA. 2012. Clinical neuroscience of addiction: applications to psychological science and practice. Clin. Psychol. Sci. Pract. 19:2154–66
     [Google Scholar]
  115. Ray LA, Bujarski S, Grodin E, Hartwell E, Green R et al. 2019a. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am. J. Drug Alcohol Abuse 45:2124–40 https://doi.org/10.1080/00952990.2018.1528265
    [Crossref] [Google Scholar]
  116. Ray LA, Bujarski S, Roche DJO. 2016. Subjective response to alcohol as a research domain criterion. Alcohol. Clin. Exp. Res. 40:16–17 https://doi.org/10.1111/acer.12927
    [Crossref] [Google Scholar]
  117. Ray LA, Bujarski S, Roche DJO, Magill M. 2018. Overcoming the “valley of death” in medications development for alcohol use disorder. Alcohol. Clin. Exp. Res. 42:91612–22
     [Google Scholar]
  118. Ray LA, Bujarski S, Shoptaw S, Roche DJO, Heinzerling K, Miotto K. 2017a. Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial. Neuropsychopharmacology 42:91776–88 https://doi.org/10.1038/npp.2017.10
    [Crossref] [Google Scholar]
  119. Ray LA, Bujarski S, Yardley MM, Roche DJO, Hartwell EE. 2017b. Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: Do they matter?. Am. J. Drug Alcohol Abuse 43:6703–10 https://doi.org/10.1080/00952990.2017.1312423
    [Crossref] [Google Scholar]
  120. Ray LA, Courtney KE, Hutchison KE, MacKillop J, Galvan A, Ghahremani DG. 2014. Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues. Alcohol. Clin. Exp. Res. 38:178–89 https://doi.org/10.1111/acer.12136
    [Crossref] [Google Scholar]
  121. Ray LA, Du H, Grodin E, Bujarski S, Meredith L et al. 2020. Capturing habitualness of drinking and smoking behavior in humans. Drug Alcohol Depend 207:107738 https://doi.org/10.1016/j.drugalcdep.2019.107738
    [Crossref] [Google Scholar]
  122. Ray LA, Grodin EN, Leggio L, Bechtholt AJ, Becker H et al. 2021. The future of translational research on alcohol use disorder. Addict. Biol. 26:2e12903
     [Google Scholar]
  123. Ray LA, Hutchison KE. 2004. A polymorphism of the μ-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol. Clin. Exp. Res. 28:121789–95 https://doi.org/10.1097/01.ALC.0000148114.34000.B9
    [Crossref] [Google Scholar]
  124. Ray LA, Hutchison KE. 2007. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 64:91069–77 https://doi.org/10.1001/archpsyc.64.9.1069
    [Crossref] [Google Scholar]
  125. Ray LA, Lim AC, Shoptaw S 2019b. What defines a clinically meaningful outcome in the treatment of substance use disorders: ‘Getting your life back.’ Addiction. 114118–20 https://doi.org/10.1111/add.14455
    [Crossref]
  126. Ray LA, MacKillop J, Monti PM. 2010. Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. Subst. Use Misuse 45:111742–65 https://doi.org/10.3109/10826084.2010.482427
    [Crossref] [Google Scholar]
  127. Reilly MT, Noronha A, Goldman D, Koob GF. 2017. Genetic studies of alcohol dependence in the context of the addiction cycle. Neuropharmacology 122:3–21 https://doi.org/10.1016/j.neuropharm.2017.01.017
    [Crossref] [Google Scholar]
  128. Robinson TE, Berridge KC. 1993. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Brain Res. Rev. 18:3247–91
     [Google Scholar]
  129. Robinson TE, Berridge KC. 2001. Incentive-sensitization and addiction. Addiction 96:1103–14
     [Google Scholar]
  130. Robinson TE, Berridge KC. 2008. The incentive sensitization theory of addiction: some current issues. Philos. Trans. R. Soc. B 363: 1507.3137–46 https://doi.org/10.1098/rstb.2008.0093
    [Crossref] [Google Scholar]
  131. Roche DJ, Ray LA. 2015. Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. Pharmacogenomics 16:7721–36
     [Google Scholar]
  132. Rogers G, Keating D, Young R, Wong M, Licinio J, Wesselingh S. 2016. From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Mol. Psychiatry 21:6738–48
     [Google Scholar]
  133. Rohn MC, Lee MR, Kleuter SB, Schwandt ML, Falk DE, Leggio L. 2017. Differences between treatment-seeking and nontreatment-seeking alcohol-dependent research participants: an exploratory analysis. Alcohol. Clin. Exp. Res. 41:2414–20 https://doi.org/10.1111/acer.13304
    [Crossref] [Google Scholar]
  134. Roman M, Irwin MR. 2020. Novel neuroimmunologic therapeutics in depression: a clinical perspective on what we know so far. Brain Behav. Immun. 83:7–21 https://doi.org/10.1016/j.bbi.2019.09.016
    [Crossref] [Google Scholar]
  135. Røysamb E, Kendler KS, Tambs K, Ørstavik RE, Neale MC et al. 2011. The joint structure of DSM-IV Axis I and Axis II disorders. J. Abnorm. Psychol. 120:1198–209 https://doi.org/10.1037/a0021660
    [Crossref] [Google Scholar]
  136. Sanislow CA, Pine DS, Quinn KJ, Kozak MJ, Garvey MA et al. 2010. Developing constructs for psychopathology research: Research Domain Criteria. J. Abnorm. Psychol. 119:4631–39 https://doi.org/10.1037/a0020909
    [Crossref] [Google Scholar]
  137. Satel SL, Lilienfeld SO. 2017. If addiction is not best conceptualized a brain disease, then what kind of disease is it?. Neuroethics 10:119–24
     [Google Scholar]
  138. Schacht JP, Anton RF, Myrick H. 2013. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict. Biol. 18:1121–33 https://doi.org/10.1111/j.1369-1600.2012.00464.x
    [Crossref] [Google Scholar]
  139. Schultz W, Dayan P, Montague PR. 1997. A neural substrate of prediction and reward. Science 275:53061593–99
     [Google Scholar]
  140. Sebold M, Nebe S, Garbusow M, Guggenmos M, Schad DJ et al. 2017. When habits are dangerous: Alcohol expectancies and habitual decision making predict relapse in alcohol dependence. Biol. Psychiatry 82:11847–56 https://doi.org/10.1016/j.biopsych.2017.04.019
    [Crossref] [Google Scholar]
  141. Sjoerds Z, de Wit S, van den Brink W, Robbins TW, Beekman ATF et al. 2013. Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients. Transl. Psychiatry 3:e337 https://doi.org/10.1038/tp.2013.107
    [Crossref] [Google Scholar]
  142. Smith KS, Graybiel AM. 2016. Habit formation. Dialogues Clin. Neurosci. 18:133–43
     [Google Scholar]
  143. Snoek A. 2017. How to recover from a brain disease: Is addiction a disease, or is there a disease-like stage in addiction?. Neuroethics 10:1185–94
     [Google Scholar]
  144. Sofuoglu M, Mooney M, Kosten T, Waters A, Hashimoto K. 2011. Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans. Psychopharmacology 213:161–68 https://doi.org/10.1007/s00213-010-2014-5
    [Crossref] [Google Scholar]
  145. Solomon RL, Corbit JD. 1974. An opponent-process theory of motivation. I. Temporal dynamics of affect. Psychol. Rev. 81:2119–45
     [Google Scholar]
  146. Tate SK, Goldstein DB. 2004. Will tomorrow's medicines work for everyone?. Nat. Genet. 36:11 SupplS34–42
     [Google Scholar]
  147. Teachman BA, McKay D, Barch DM, Prinstein MJ, Hollon SD, Chambless DL. 2019. How psychosocial research can help the National Institute of Mental Health achieve its grand challenge to reduce the burden of mental illnesses and psychological disorders. Am. Psychol. 74:4415–31
     [Google Scholar]
  148. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R et al. 2018. The gut–liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 15:7397–411
     [Google Scholar]
  149. van Dorn A. 2017. Joshua Gordon: an interdisciplinary approach to mental health. Lancet Psychiatry 4:4279 https://doi.org/10.1016/S2215-0366(17)30093-7
    [Crossref] [Google Scholar]
  150. Vandaele Y, Janak PH. 2018. Defining the place of habit in substance use disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 87:Part A22–32 https://doi.org/10.1016/j.pnpbp.2017.06.029
    [Crossref] [Google Scholar]
  151. Venniro M, Zhang M, Caprioli D, Hoots JK, Golden SA et al. 2018. Volitional social interaction prevents drug addiction in rat models. Nat. Neurosci. 21:111520–29 https://doi.org/10.1038/s41593-018-0246-6
    [Crossref] [Google Scholar]
  152. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D et al. 2001. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J. Neurosci. 21:239414–18
     [Google Scholar]
  153. Volkow ND, Koob GF, McLellan AT. 2016. Neurobiologic advances from the brain disease model of addiction. N. Engl. J. Med. 374:4363–71
     [Google Scholar]
  154. Volkow ND, Li TK. 2005. The neuroscience of addiction. Nat. Neurosci. 8:111429–30 https://doi.org/10.1038/nn1105-1429
    [Crossref] [Google Scholar]
  155. Volkow ND, Morales M. 2015. The brain on drugs: from reward to addiction. Cell 162:4712–25 https://doi.org/10.1016/j.cell.2015.07.046
    [Crossref] [Google Scholar]
  156. Vollstädt-Klein S, Wichert S, Rabinstein J, Bühler M, Klein O et al. 2010. Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum. Addiction 105:101741–49 https://doi.org/10.1111/j.1360-0443.2010.03022.x
    [Crossref] [Google Scholar]
  157. Voon V, Derbyshire K, Rück C, Irvine MA, Worbe Y et al. 2015. Disorders of compulsivity: a common bias towards learning habits. Mol. Psychiatry 20:3345–52 https://doi.org/10.1038/mp.2014.44
    [Crossref] [Google Scholar]
  158. Wagner FA, Anthony JC. 2002. From first drug use to drug dependence: developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 26:4479–88 https://doi.org/10.1016/s0893-133x(01)00367-0
    [Crossref] [Google Scholar]
  159. Walters RK, Polimanti R, Johnson EC, McClintick JN, Adams MJ et al. 2018. Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. Nat. Neurosci. 21:121656–69 https://doi.org/10.1038/s41593-018-0275-1
    [Crossref] [Google Scholar]
  160. Weiss F, Martin-Fardon R, Ciccocioppo R, Kerr TM, Smith DL, Ben-Shahar O. 2001. Enduring resistance to extinction of cocaine-seeking behavior induced by drug-related cues. Neuropsychopharmacology 25:3361–72 https://doi.org/10.1016/S0893-133X(01)00238-X
    [Crossref] [Google Scholar]
  161. Weiss F, Parsons LH, Schulteis G, Hyytia P, Lorang MT et al. 1996. Ethanol self-administration restores withdrawal-associated deficiencies in accumbal dopamine and 5-hydroxytryptamine release in dependent rats. J. Neurosci. 16:103474–85
     [Google Scholar]
  162. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G et al. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 2:6699–703
     [Google Scholar]
  163. Wise RA. 2008. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox. Res. 14:2–3169–83 https://doi.org/10.1007/BF03033808
    [Crossref] [Google Scholar]
  164. Wong M, Inserra A, Lewis M, Mastronardi CA, Leong L et al. 2016. Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. Mol. Psychiatry 21:6797–805
     [Google Scholar]
  165. Worley MJ, Heinzerling KG, Roche DJ, Shoptaw S. 2016. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug Alcohol Depend 162:245–50
     [Google Scholar]
  166. Zarrinpar A, Chaix A, Xu ZZ, Chang MW, Marotz CA et al. 2018. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. Nat. Commun. 9:12872 https://doi.org/10.1038/s41467-018-05336-9
    [Crossref] [Google Scholar]
  167. Zuk O, Hechter E, Sunyaev SR, Lander ES 2012. The mystery of missing heritability: Genetic interactions create phantom heritability. PNAS 109:41193–98 https://doi.org/10.1073/pnas.1119675109
    [Crossref] [Google Scholar]
/content/journals/10.1146/annurev-clinpsy-081219-114309
Loading
  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error